Patents Examined by Brian E McDowell
  • Patent number: 10640516
    Abstract: The invention relates to novel phosphoinositide 3-kinase (PI3k), mammalian target of rapamycin (mTOR) and PI3k-related kinase (PIKKs) inhibitor compounds of formula (I), wherein X1, X2 and X3 are N or CH, with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH, These compounds are useful, either alone or in combination with further therapeutic agents, for treating disorders mediated by lipid kinases.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: May 5, 2020
    Assignees: PIQUR THERAPEUTICS AG, UNIVERSITÄT BASEL
    Inventors: Vladimir Cmiljanovic, Paul Hebeisen, Florent Beaufils, Thomas Bohnacker, Denise Rageot, Alexander Sele, Matthias Wymann, Jean-Baptiste Langlois
  • Patent number: 10626133
    Abstract: To provide an electrochromic compound, represented by the following general formula where X1, X2, X3, X4, X5, X6, X7 and X8 are each independently a hydrogen atom or a monovalent substituent; R1 and R2 are each independently a monovalent substituent; A? and B? are each independently a monovalent anion; and Y is represented by the following general formula (II) or (III): where X9, X10, X11, X12, X13, X14, X15, X16, X17, and X18 are each independently a hydrogen atom or a monovalent substituent.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: April 21, 2020
    Assignee: Ricoh Company, Ltd.
    Inventors: Toshiya Sagisaka, Hiroyuki Takahashi, Takashi Okada, Shigenobu Hirano, Tohru Yashiro, Koh Fujimura, Yoshihisa Naijo, Yoshinori Okada, Kazuaki Tsuji, Sukchan Kim, Keiichiroh Yutani, Tamotsu Horiuchi, Mamiko Inoue
  • Patent number: 10626327
    Abstract: An organic light emitting diode includes a light emitting layer that includes a light emitting material of the constitutional formula The structure is unitary, and the formula weight is determined, and the better solubility and film formation are provided, and the thin film status is stable; it possesses a very high decomposition temperature and a lower sublimation temperature, and is easy to sublime to be light emitting material of high purity, and can be applied for small molecule organic light emitting diode. In the method for manufacturing the light emitting material, p-bromothiophenol and 4-Bromo-2-fluorobenzonitrile are employed to be starting materials, and an intermediate of the light emitting material is obtained with a series of simple reactions, and finally, the light emitting material is obtained with Ullmann reaction or Suzuki reaction, and these steps are simple and the production is high.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: April 21, 2020
    Assignee: TCL CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD.
    Inventors: Xianjie Li, Yuanchun Wu, Shijian Su, Yunchuan Li
  • Patent number: 10611786
    Abstract: Reactions that directly install nitrogen into C—H bonds of complex molecules are significant because of their potential to change the chemical and biological properties of a given compound. Selective intramolecular C—H amination reactions that achieve high levels of reactivity, while maintaining excellent site-selectivity and functional-group tolerance is a challenging problem. Herein is reported a manganese perchlorophthalocyanine catalyst [MnIII(ClPc)] for intermolecular benzylic C—H amination of bioactive molecules and natural products that proceeds with unprecedented levels of reactivity and site-selectivity. In the presence of Brønsted or Lewis acid, the [MnIII(ClPc)]-catalyzed C—H amination demonstrates unique tolerance for tertiary amine, pyridine and benzimidazole functionalities. Mechanistic studies indicate that C—H amination proceeds through an electrophilic metallonitrene intermediate via a stepwise pathway where C—H cleavage is the rate-determining step of the reaction.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: April 7, 2020
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: M. Christina White, Joseph R. Clark, Kaibo Feng, Anasheh Sookezian, Chloe Wendell
  • Patent number: 10597399
    Abstract: A class of substituted triazolopiperazine compounds represented by formula (I), tautomers, enantiomers, diastereomers, racemates, metabolites, metabolic precursors, and pharmaceutically acceptable salts, esters, prodrugs or hydrate thereof, a preparation methods therefor, intermediates and a use thereof in the preparation of drugs for prevention and treatment of diseases associated with PARP including various ischemic diseases, neurodegenerative diseases and cancers.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: March 24, 2020
    Assignee: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Ao Zhang, Zehong Miao, Pingyuan Wang, Shanshan Song, Zilan Song, Xiajuan Huan, Zhoulong Fan, Jian Ding
  • Patent number: 10596175
    Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: March 24, 2020
    Assignee: Novartis AG
    Inventors: Agnes Biggart, Fang Liang, Casey Jacob Nelson Mathison, Valentina Molteni, Advait Suresh Nagle, Frantisek Supek, Vince Yeh
  • Patent number: 10597376
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds as exemplified as follows, The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: March 24, 2020
    Assignee: Celgene Quanticel Research, Inc.
    Inventors: Young K. Chen, Toufike Kanouni, Jeffrey Alan Stafford, James Marvin Veal
  • Patent number: 10590146
    Abstract: The present invention relates to compounds of formula (I), wherein R1 to R4 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: March 17, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Lisha Wang, Hongying Yun, Xiufang Zheng
  • Patent number: 10577353
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: March 3, 2020
    Assignee: ViiV HEALTHCARE UK (NO.5) LIMITED
    Inventors: John F. Kadow, B. Narasimhulu Naidu, Tao Wang, Zhiwei Yin, Zhongxing Zhang
  • Patent number: 10577537
    Abstract: A method for manufacturing a light emitting material of the constitutional formula is provided. The structure is unitary, and the formula weight is determined, and the better solubility and film formation are provided, and the thin film status is stable; it possesses a very high decomposition temperature and a lower sublimation temperature, and is easy to sublime to be light emitting material of high purity, and can be applied for small molecule organic light emitting diode. In the method for manufacturing the light emitting material, p-bromothiophenol and 4-Bromo-2-fluorobenzonitrile are employed to be starting materials, and an intermediate of the light emitting material is obtained with a series of simple reactions, and finally, the light emitting material is obtained with Ullmann reaction or Suzuki reaction, and these steps are simple and the production is high.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: March 3, 2020
    Assignee: TCL CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD.
    Inventors: Xianjie Li, Yuanchun Wu, Shijian Su, Yunchuan Li
  • Patent number: 10577343
    Abstract: Provided is a compound represented by formula (I): or an N-oxide compound thereof, wherein the variable groups are as defined in the specification. Also provided is an arthropod pest control agent containing a compound represented by formula (I) and an inert carrier. The compound represented by formula (I) and arthropod pest control agent exhibit an excellent controlling effect against arthropod pests.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: March 3, 2020
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Kohei Orimoto, Yoshihiko Nokura, Yuji Nakajima, Takamasa Tanabe, Takahiro Kimura
  • Patent number: 10550091
    Abstract: In an aspect, the invention relates to 1,4,5-substituted 1,2,3-triazole and 1,2,4,5-substituted imidazoles, which are modulators the pregnane X receptor (“PXR”); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of modulating an adverse drug reaction in a mammal using the compounds and pharmaceutical compositions; methods of treatment of a disorder of uncontrolled cellular proliferation, such as a cancer, using the compounds and pharmaceutical compositions; methods of modulating pregnane X receptor activity in a mammal using the compounds and pharmaceutical compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: February 4, 2020
    Assignee: St. Jude Children's Research Hospital
    Inventors: Taosheng Chen, Wenwei Lin, Yueming Wang
  • Patent number: 10544105
    Abstract: Provided herein are dUTPase inhibitors of Formula (I), compositions comprising such compounds and methods of using such compounds and compositions
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: January 28, 2020
    Assignee: CV6 THERAPEUTICS (NI) LIMITED
    Inventors: Mark Spyvee, Pravin S. Shirude
  • Patent number: 10538501
    Abstract: The present invention provides PI3K protein kinase modulators of Formula (I) wherein R, R1,R2,L1, Cy1 and Cy2 are as disclosed herein, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: January 21, 2020
    Assignee: Rhizen Pharmaceuticals SA
    Inventors: Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Swaroop K. Vakkalanka
  • Patent number: 10533024
    Abstract: Embodiments describe methods of synthesizing metal mesoporphyrin compounds. In embodiments, a metal mesoporphyrin compound may be formed by hemin transmetallation and subsequent hydrogenation of the tin protoporphyrin IX to form a metal mesoporphyrin. In other embodiments, a method of synthesizing a metal mesoporphyrin compound comprises forming a protoporphyrin methyl ester from hemin and converting the protoporphyrin methyl ester intermediate to a metal mesoporphyrin compound through metal insertion and hydrogenation. In other embodiments, a metal mesoporphyrin compound may be formed from hemin by a hydrogen-free hydrogenation method to form a mesoporphyrin IX intermediate followed by metal insertion and hydrogenation. In embodiments, a method of synthesizing a metal mesoporphyrin compound comprises forming a mesoporphyrin IX dihydrochloride intermediate compound and converting the mesoporphyrin IX intermediate to a metal mesoporphyrin compound through metal insertion.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: January 14, 2020
    Assignee: MALLINCKRODT HOSPTIAL PRODUCTS IP LIMITED
    Inventors: Christopher P. Boucher, David Roe
  • Patent number: 10532042
    Abstract: Provided herein are KRAS G12C inhibitors, compounds of formula (II), or a pharmaceutically acceptable salt thereof: compositions of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: January 14, 2020
    Assignee: Amgen Inc.
    Inventors: Brian Alan Lanman, Victor J. Cee, Alexander J. Pickrell, Anthony B. Reed, Kevin C. Yang, David John Kopecky, Hui-Ling Wang, Patricia Lopez, Kate Ashton, Shon Booker, Christopher M. Tegley
  • Patent number: 10526323
    Abstract: Compounds, including those of the following formula: wherein the variables are defined herein, which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: January 7, 2020
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Corey R. Hopkins, Craig W. Lindsley, Colleen M. Niswender, Darren W. Engers, Joe Panarese, Joanne Bronson, Yong-Jin Wu, Jason Guernon
  • Patent number: 10526325
    Abstract: Compounds of the formula Ia or of the formula Ib in which X, Y, R1 and R2 have the meanings indicated in claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: January 7, 2020
    Assignee: Merck Patent GmbH
    Inventor: Hans-Peter Buchstaller
  • Patent number: 10519148
    Abstract: The present invention relates to an acrylic acid derivative as shown in general formula (I), a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, the preparation method thereof, a pharmaceutical composition containing same, and the use thereof as therapeutic agents, in particular as selective estrogen receptor degraders (SERD), wherein the substituents of general formula (I) are the same as those defined in the description.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: December 31, 2019
    Assignee: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Dongliang Guan, Shouyi Sheng, Hua Bai
  • Patent number: 10513516
    Abstract: The present invention includes novel aminothiazole compounds of formula (I) useful in preventing or treating cancer in a subject in need thereof. The present invention also includes methods of preventing or treating cancer in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the invention.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: December 24, 2019
    Assignee: Temple University—Of The Commonwealth System of Higher Education
    Inventors: Jean-Pierre J. Issa, Hanghang Zhang, Magid Abu-Gharbia, Wayne E. Childers, George C. Morton